Hikma Pharmaceuticals Public annual total debt
2020
2021
2022
2023
2024
2025
Hikma Pharmaceuticals Public Total Debt Growth & History (HIK)
Hikma Pharmaceuticals Public's total debt was $1.60B for fiscal 2025.
View full Hikma Pharmaceuticals Public company overviewHikma Pharmaceuticals Public annual total debt history
| Fiscal year | Period ended | Total debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.60B | $298.0M | +22.82% |
| 2024 | 2024-12-31 | $1.31B | $115.0M | +9.66% |
| 2023 | 2023-12-31 | $1.19B | −$92.0M | −7.17% |
| 2022 | 2022-12-31 | $1.28B | $437.0M | +51.65% |
| 2021 | 2021-12-31 | $846.0M | −$86.0M | −9.23% |
| 2020 | 2020-12-31 | $932.0M | — | — |
Hikma Pharmaceuticals Public quarterly total debt
Q4.24
Q2.25
Q4.25
Q2.26
| Fiscal quarter | Period ended | Total debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.96B | $399.0M | +25.61% |
| Q4 2025 | 2025-12-31 | $1.60B | $298.0M | +22.82% |
| Q2 2025 | 2025-06-30 | $1.56B | — | — |
| Q4 2024 | 2024-12-31 | $1.31B | — | — |
Hikma Pharmaceuticals Public total debt trends
Over the last five fiscal years, Hikma Pharmaceuticals Public's total debt increased from $932.0M to $1.60B, a change of $672.0M. The latest reported quarter, Q2 2026, shows $1.96B.
About the metric
What total debt means
Total debt measures a company’s reported interest-bearing borrowing obligations at a reporting-period end. It can include short-term borrowings, current maturities, long-term debt, and finance lease obligations when they are included in the company’s debt facts.
Calculation and source
reported and combined total debt
TickerStat uses a reported aggregate debt value when available. Otherwise, it combines non-overlapping current and noncurrent debt facts from official filings. Total liabilities are not treated as debt, and missing debt is not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hikma Pharmaceuticals Public source filings ↗Community posts
Hikma’s epinephrine nasal spray advances into regulatory review
Hikma ($HIK) said regulators in the United States, Europe and the UK have accepted submissions for its investigational epinephrine nasal spray for review. The company has also filed in Canada and intends to expand submissions to additional ...